LEADER 04228nam 2201057z- 450 001 9910557112003321 005 20231214132827.0 035 $a(CKB)5400000000040926 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/69328 035 $a(EXLCZ)995400000000040926 100 $a20202105d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aNew Aspects of Cancer Stem Cell Biology$eImplications for Innovative Therapies 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 electronic resource (208 p.) 311 $a3-03943-406-3 311 $a3-03943-407-1 330 $aThe cancer stem cell (CSC) paradigm represents one of the most prominent breakthroughs of the last decades in tumor biology. CSCs are that subpopulation within a tumor that can survive conventional therapies and as a consequence are able to fuel tumor recurrence. Nevertheless, the biological characteristics of CSCs and even their existence, remain the main topic among tumor biologists debates. The difficulty in achieving a better definition of CSC biology may actually be explained by the plasticity of such a cell subpopulation. Indeed, the emerging view is that CSCs represent a dynamic ?state? of tumor cells that can acquire stemness-related properties under specific circumstances, rather than referring to a well-defined group of cells. Regardless of their origin, it is clear that designing novel antitumor treatments based on the eradication of CSCs will only be possible upon unraveling the biological mechanisms that underlie their pathogenic role in tumor progression and therapy resistance. The Special Issue on ?New aspects of cancer stem cell biology: implications for innovative therapies? aims at highlighting recent insights into CSC features that can make them an attractive target for novel therapeutic strategies. 517 $aNew Aspects of Cancer Stem Cell Biology 606 $aResearch & information: general$2bicssc 606 $aBiology, life sciences$2bicssc 610 $aCadherin 11 610 $aWNT signaling 610 $a?-catenin 610 $acancer stem cells 610 $aTNBC 610 $aearly breast cancer 610 $abevacizumab 610 $aneoadjuvant chemotherapy 610 $aALDH1 610 $asolid cancer 610 $achemo-resistance 610 $aHDAC inhibitors 610 $ahead and neck squamous cell carcinoma 610 $aSRC 610 $adasatinib 610 $asaracatinib 610 $aEC-8042 610 $aOvarian cancer 610 $aWnt signaling 610 $atumor progression 610 $atherapy resistance 610 $aexosomes 610 $aoral cancer risk 610 $aoral epithelial dysplasia 610 $aSOX2 610 $aimmunohistochemistry 610 $aoral squamous cell carcinoma 610 $agenome-wide 610 $atranscriptome 610 $alung cancer 610 $aATAC-seq 610 $aRNA-seq 610 $aCSCs 610 $aNSCLC 610 $aB4GALT1 610 $aLUAD 610 $abreast cancer 610 $alipid 610 $ametabolism 610 $atherapeutic resistance 610 $abowel cancer 610 $aorganoid 610 $atumoroid 610 $acolorectal 610 $acolon 610 $astem cell 610 $achemotherapy resistance 610 $aovarian cancer 610 $acancer stem cell 610 $agenetic heterogeneity 610 $aSNP array 610 $aL1CAM 610 $achemoresistance 610 $aepithelial-mesenchymal transition 610 $acancer therapy 610 $acell adhesion molecule 615 7$aResearch & information: general 615 7$aBiology, life sciences 700 $aCavallaro$b Ugo$4edt$0406773 702 $aGiordano$b Marco$4edt 702 $aCavallaro$b Ugo$4oth 702 $aGiordano$b Marco$4oth 906 $aBOOK 912 $a9910557112003321 996 $aNew Aspects of Cancer Stem Cell Biology$93021982 997 $aUNINA